side effects of glp-1 receptor agonists Frontiers Unraveling the safety profile of

In the ongoing SURPASS-CVOT trial (ClinicalTrials.gov ID NCT04255433), the safety of tirzepatide versus GLP-1RA dulaglutide is assessed in patients living with T2DM with confirmed atherosclerotic CVD, including participants treated with insulin and SGLT2 inhibitors, where the composite primary outcome will be the time to first occurrence of MACE

[DOI] [PMC free article] [PubMed] [Google Scholar] 147.Zhu R, et al

We explore the markets dynamic reshaping, the key macro and micro drivers fueling its exponential growth, and the strategic differentiation required for a crowded pipeline

Policy and Reimbursement: Closing the Access Gap Policy developments will be a trend across 2026

The Danish guidelines suggest a dosage of 1.8 mg daily in women with diabetes or 3.0 mg daily in women with obesity for liraglutide, and 1.0 mg once weekly for semaglutide for treatment of patients with type 2 diabetes or 2.4 mg once weekly for patients with obesity (Dansk Endokrinologisk Selskab, 2023)

Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology